Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pembrolizumab + Defactinib In Pleural Mesothelioma
NCT04201145 · Raphael Bueno, MD · PHASE1 · withdrawn · last registry update 2020-11-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding complications coupled with competing scientific objectives” | – | Registry record, Raphael Bueno, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-09-17Phase 3 first posted: AstraZeneca, Trastuzumab Deruxtecan + Cisplatin (NCT05048797)
- 2021-09-14Results posted on the registry: Immunocore Ltd, IMCgp100 + Dacarbazine (NCT03070392)
- 2021-02-03Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Belzutifan (NCT04736706)
- 2020-11-03Phase 3 first posted: Mirati Therapeutics Inc., Adagrasib + Adagrasib (NCT04613596)
- 2020-09-01Phase 3 first posted: BioNTech SE, BNT113 + Pembrolizumab (NCT04534205)
- 2020-02-13Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT04267848)
- 2020-01-09Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Placebo for pembrolizumab (NCT04221945)
- 2019-12-24Phase 3 first posted: Merck Sharp & Dohme LLC, pembrolizumab + placebo (NCT04210115)
- 2019-12-11Phase 3 first posted: Eli Lilly and Company, Selpercatinib + Carboplatin (NCT04194944)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision